Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy. Histone deacetylases (HDAC) are commonly dysregulated in cancer and therefore represent promising targets for therapies, however their role in HCC pathogenesis is...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lachenmayer, Anja, Toffanin, Sara, Cabellos, Laia, Alsinet, Clara, Hoshida, Yujin, Villanueva, Augusto, Minguez, Beatriz, Tsai, Hung-Wen, Ward, Stephen C., Thung, Swan, Friedman, Scott L., Llovet, Josep M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3355195/
https://ncbi.nlm.nih.gov/pubmed/22322234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2012.01.009
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados